PLAT and intracranial hemorrhage: Nonetheless, patients treated with TNK-tPA are still at risk of developing symptomatic intracranial hemorrhage so the ability of PMX205 to inhibit this capacity of TNK-tPA also has potential therapeutic implications if TNK-tPA is to become the preferred thrombolytic for AIS.